133 related articles for article (PubMed ID: 12655574)
1. Haplotype analysis of the BRCA2 9254delATCAT recurrent mutation in breast/ovarian cancer families from Spain.
Campos B; Díez O; Odefrey F; Domènech M; Moncoutier V; Martínez-Ferrandis JI; Osorio A; Balmaña J; Barroso A; Armengod ME; Benítez J; Alonso C; Stoppa-Lyonnet D; Goldgar D; Baiget M
Hum Mutat; 2003 Apr; 21(4):452. PubMed ID: 12655574
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.
Infante M; Durán M; Acedo A; Pérez-Cabornero L; Sanz DJ; García-González M; Beristain E; Esteban-Cardeñosa E; de la Hoya M; Teulé A; Vega A; Tejada MI; Lastra E; Miner C; Velasco EA
Clin Genet; 2010 Jan; 77(1):60-9. PubMed ID: 19912264
[TBL] [Abstract][Full Text] [Related]
3. Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Díez O; Osorio A; Durán M; Martinez-Ferrandis JI; de la Hoya M; Salazar R; Vega A; Campos B; Rodríguez-López R; Velasco E; Chaves J; Díaz-Rubio E; Jesús Cruz J; Torres M; Esteban E; Cervantes A; Alonso C; San Román JM; González-Sarmiento R; Miner C; Carracedo A; Eugenia Armengod M; Caldés T; Benítez J; Baiget M
Hum Mutat; 2003 Oct; 22(4):301-12. PubMed ID: 12955716
[TBL] [Abstract][Full Text] [Related]
4. Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain.
Llort G; Muñoz CY; Tuser MP; Guillermo IB; Lluch JR; Bale AE; Franco MA
Hum Mutat; 2002 Mar; 19(3):307. PubMed ID: 11857748
[TBL] [Abstract][Full Text] [Related]
5. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Gutiérrez-Enríquez S; de la Hoya M; Martínez-Bouzas C; Sanchez de Abajo A; Ramón y Cajal T; Llort G; Blanco I; Beristain E; Díaz-Rubio E; Alonso C; Tejada MI; Caldés T; Diez O
Breast Cancer Res Treat; 2007 May; 103(1):103-7. PubMed ID: 17063271
[TBL] [Abstract][Full Text] [Related]
6. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations.
Gallardo M; Silva A; Rubio L; Alvarez C; Torrealba C; Salinas M; Tapia T; Faundez P; Palma L; Riccio ME; Paredes H; Rodriguez M; Cruz A; Rousseau C; King MC; Camus M; Alvarez M; Carvallo P
Breast Cancer Res Treat; 2006 Jan; 95(1):81-7. PubMed ID: 16261400
[TBL] [Abstract][Full Text] [Related]
7. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
[TBL] [Abstract][Full Text] [Related]
8. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
9. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
[TBL] [Abstract][Full Text] [Related]
10. Haplotype analysis in Icelandic and Finnish BRCA2 999del5 breast cancer families.
Barkardottir RB; Sarantaus L; Arason A; Vehmanen P; Bendahl PO; Kainu T; Syrjäkoski K; Krahe R; Huusko P; Pyrhönen S; Holli K; Kallioniemi OP; Egilsson V; Kere J; Nevanlinna H
Eur J Hum Genet; 2001 Oct; 9(10):773-9. PubMed ID: 11781689
[TBL] [Abstract][Full Text] [Related]
11. BRCA2 founder mutation in Slovenian breast cancer families.
Krajc M; De Grève J; Goelen G; Teugels E
Eur J Hum Genet; 2002 Dec; 10(12):879-82. PubMed ID: 12461697
[TBL] [Abstract][Full Text] [Related]
12. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
13. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
14. Two founder BRCA2 mutations predispose to breast cancer in young women.
Infante M; Durán M; Lasa A; Acedo A; de la Hoya M; Esteban-Cardeñosa E; Sanz DJ; Pérez-Cabornero L; Lastra E; Miner C; Velasco EA
Breast Cancer Res Treat; 2010 Jul; 122(2):567-71. PubMed ID: 19949853
[TBL] [Abstract][Full Text] [Related]
15. A single BRCA2 mutation in male and female breast cancer families from Iceland with varied cancer phenotypes.
Thorlacius S; Olafsdottir G; Tryggvadottir L; Neuhausen S; Jonasson JG; Tavtigian SV; Tulinius H; Ogmundsdottir HM; Eyfjörd JE
Nat Genet; 1996 May; 13(1):117-9. PubMed ID: 8673089
[TBL] [Abstract][Full Text] [Related]
16. The western Swedish BRCA1 founder mutation 3171ins5; a 3.7 cM conserved haplotype of today is a reminiscence of a 1500-year-old mutation.
Bergman A; Einbeigi Z; Olofsson U; Taib Z; Wallgren A; Karlsson P; Wahlström J; Martinsson T; Nordling M
Eur J Hum Genet; 2001 Oct; 9(10):787-93. PubMed ID: 11781691
[TBL] [Abstract][Full Text] [Related]
17. BRCA1 and BRCA2 mutations in breast/ovarian cancer patients from central Italy.
Stuppia L; Di Fulvio P; Aceto G; Pintor S; Veschi S; Gatta V; Colosimo A; Cianchetti E; Cama A; Mariani-Costantini R; Battista P; Palka G
Hum Mutat; 2003 Aug; 22(2):178-9. PubMed ID: 12872265
[TBL] [Abstract][Full Text] [Related]
18. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
19. Hereditary breast and ovarian cancer in Cyprus: identification of a founder BRCA2 mutation.
Hadjisavvas A; Charalambous E; Adamou A; Neuhausen SL; Christodoulou CG; Kyriacou K
Cancer Genet Cytogenet; 2004 Jun; 151(2):152-6. PubMed ID: 15172753
[TBL] [Abstract][Full Text] [Related]
20. The c.156_157insAlu BRCA2 rearrangement accounts for more than one-fourth of deleterious BRCA mutations in northern/central Portugal.
Peixoto A; Santos C; Rocha P; Pinheiro M; Príncipe S; Pereira D; Rodrigues H; Castro F; Abreu J; Gusmão L; Amorim A; Teixeira MR
Breast Cancer Res Treat; 2009 Mar; 114(1):31-8. PubMed ID: 18363094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
